The article is a topical literature review of the place of percutaneous coronary interventions in the structure of elective revascularisation procedures, preoperative preparation of patients with stable ischaemic heart disease before percutaneous coronary intervention, the prospects of the technique, taking into account the latest advances in intervention cardiology (intravascular methods for assessing the hemodynamic signifi cance of stenosis, drug eluting stents). Modern data of the early and long-term results of percutaneous coronary intervention are presented, the predictable potentially modifi able risks of adverse events are described, and ways to correct them are discussed. The results of randomised studies comparing the effectiveness of different approaches for managing patients with stable coronary heart disease (medical therapy, percutaneous coronary intervention) are presented, and prospects for using new drugs to improve the early and late outcomes of endovascular revascularisation are discussed.
Introduction
Cardiovascular diseases hold the leading position in the structure of morbidity in employable population. Ischaemic heart disease is a widely spread cardiovascular pathology and optimisation of guidance for such patients is relevant to practical healthcare in the whole world. Development and wide introduction of less invasive coronary artery blood fl ow restoration methods and elimination of myocardial ischaemia symptoms facilitates maintenance of the patients' quality of life. These methods do not have long-term restoration periods and are associated with fewer postoperative complications in comparison with open surgery. Percutaneous coronary interventions (PCI) play an important role in the structure of elective revascularisation procedures. The less invasive method of myocardial perfusion restoration signifi cantly improves the quality of life of patients with stable ischaemic heart disease. At the present time, it appears relevant within the framework of practical healthcare to draw attention to high-quality preoperative preparation of patients with stable ischaemic heart disease (IHD) before PCI. According to literature data, distinct negative infl uence on development of early and delayed complications after PCI may be exerted by such potentially modifi able factors as arterial blood pressure, the level of lipoproteins, glycaemia, presence of renal dysfunction as well as active smoking and excess body weight. However, a substantial part of patients hospitalised for elective PCI fail to achieve target levels of secondary prevention. According to data from different research, up to one half of patients referred to revascularisation do not receive prescribe treatment including not taking statins. Less than one half of individuals receiving optimal medical therapy reach its goals: persistent arterial blood pressure normalisation, a normal level of lipids, control over the glycaemia level in case of diabetes mellitus. Only a small number of patients with excess body weight demonstrate successful attempts to normalise it, a small part of patients cease smoking. Effi cacy of PCI as well as risk of complications during the procedure are directly associated with the quality of preoperative preparation of patients. Studying issues of preoperative guidance optimisation for stable IHD patients and development of a method for PCI patient preoperative preparation that would be functional and implementable in routine practice could signifi cantly improve short-term and long-term outcomes of the procedure.
The place of elective percutaneous coronary interventions in the structure of revascularisation procedures. Feasibility and prospects of the method
According to reported data, there was a stable trend toward growth in the total number of PCI preformed in the Russian Federation in 2018 [1] . The share of PCI in the structure of revascularisation operations is expected to grow due to increasing revascularisation availability for patients featuring elevated risk associated with open surgery (comorbidities, advanced and senile age). In stable progression of IHD, persistence of myocardial ischaemia symptoms despite optimal medical therapy (OMT), as well as improvement of the prognosis, is an indication for myocardial revascularisation (PCI of coronary artery bypass grafting (CABG)) [2] . It has been proved in a number of studies that myocardial vascularisation has advantages over OMT in the aspect of angina symptoms severity, the need for antianginals, the increase in physical exercise tolerance (ET) and general improvement of quality of life [3] . Numerous studies devoted to comparison of the two revascularisation methods (PCI and CABG) in regard to frequency of major cardiovascular events and myocardial infarction (MI) development, the necessity for repeat revascularisation leads to two main conclusions [4] [5] [6] [7] [8] [9] [10] [11] . The fi rst on lies in the fact that PCI does not provide signifi cant improvement of survivability and decrease in the number of MI during stable IHD progression notwithstanding the type of stents used. The second one lies in the fact that survivability improvement and decrease in the number of MI was demonstrated after CABG. However, the pronouncement of its effect depends on the initial coronary bed lesion severity and, probably, on presence of concomitant diabetes mellitus (DM). In particular, it is recommended for patients with the three-vessel disease and concomitant DM to undergo CABG (evidentiality class I, evidentiality level A) [12] , as well as for patients with the coronary bed lesion severity >22 according to the Syntax score (evidentiality class I, evidentiality level A) [12] . Stephan Windecker from Bern hospital notes that myocardial revascularisation is one of the most researched aspects counting over 20 randomised clinical studies comparing open and endovascular approaches, the total number of patients enrolled amounted to over 15,000. Summarising the available data, it is possible to draw a conclusion that the differences between the two methods regarding the frequence of repeat vascularisation are not eliminated through application of drugeluting stents (DES) [13] . The SYNTAX score remains the best tool to choose an optimal tactic for patients with multi-vessel disease, stenosis of the left coronary artery (LCA) and DM [12] . Daniel Thuijs presented results of the SYNTAXES study at the TCT congress in autumn 2018. Decadal results of 3/4 patients enrolled in the SYNTAX study available for analysis at this term of observation were evaluated. During the 10 years of observation, the following values were registered in 1301 patients in CABG and PCI groups: overall death-rate: 25.6% vs 29.4%, respectively, p = 0.11; in the group with the left main coronary artery lesion: 29.7% vs 31.9%, p = 0.43; in the three-vessel disease group, it was 21.9% vs 29.2%, p = 0.007, especially in high-index SYNTAX patients. In the group of patients with diabetes, lethality amounted to 36.6% after CABG and 39.4% after PCI, p = 0.45 [14] . The presented data suggests that endovascular approach to revascularisation in case of stable IHD may have long-term results comparable to such of the CABG surgery. The latest data make it possible to concern the PCI method as comparable with open myocardial revascularisation for patients with stable IHD in a number of clinical cases given modern technological equipment and objectivation of data with instrumental data. Despite PCI being a minimally invasive procedure and having lesser perioperative risks in comparison with open cardiac surgery interventions, we must strive to maintain the patient's state as satisfactory as possible not only from the clinical standpoint (chronic heart failure (CHF) compensation) but also in terms of secondary prevention of cardiovascular events (achievement of target arterial blood pressure indicators, lipidogram normalisation) before an elective revascularisation procedure. Preparation of a patient to elective PCI must include comorbidity correction and evaluation of possible contraindications to the intervention. In daily practice, the latter are erosive-ulcerative lesions in the gastrointestinal tract and, as a consequence, contraindications to undergoing dual antiplatelet therapy. Additionally, renal function assessment (the risk of acute kidney injury due to contrast injection) is given attention. Patients with indications to myocardial revascularisation have elevated risk of adverse ischaemic events within the period of waiting for the procedure. Thus, according to the metaanalysis data, one patient from eighty dies in three months while being on the CABG "patient list". The optimal waiting time before the operation is a period not exceeding 6 weeks which, in a number of cases (high functional class of angina, LCA lesions, three-vessel disease, systolic dysfunction), must be limited down to 2 weeks [15] . While advantages of PCI over the conservative approach are obvious in case of acute coronary syndrome (ACS), effects of PCI on the clinical picture of angina and hard end points for patients with stable IHD are widely discussed. Data from the COURAGE study stating that PCI does not have advantages over OMT in relation to decrease in the risk of death, MI and other major cardiovascular events were published for a long time. However, a detailed analysis of the protocol and enrollment criteria makes it clear that it is incorrect to extrapolate these results on all patients [16] . Thus, according to the published results, the participants of the study throughout the whole observation featured target values of arterial blood pressure, lipids and the DM group had the level of glycated haemoglobin at approximately 7%. In other words, the "portfolio" of the study participant was different from patients in daily practice. Since 2017, the ORBITA (ClinicalTrials.gov Identifi er: NCT02062593) study results renewed the discussion regarding feasibility of choosing PCI as a revascularisation method for patient with stable IHD [17, 18] . Scientists from the UK performed a comparison between effects of elected PCI with application of DES and OMT on ET. A total of 230 patients with stable IHD and one-vessel disease with stenosis equal to or over 70% were enrolled into the trial. All participants underwent ET assessment and were randomised into 2 groups: patients in group 1 received PCI with DES while patient in group 2 received "imitation" of intervention. After 6 weeks, all patient underwent repeat ET assessment. It was discovered that there was no difference in terms of ET between the two groups [17, 18] . However, by analogy to the COURAGE study, the data obtained should not be unambiguously interpreted as the advantage of OMT over PCI. ET improvement in patients demonstrated in the ORBITA study against the background of high-quality OMT is to be understood as a reminder about clinical importance of correction for all modifi able cardiovascular risk factors (RF) before elective interventions. Apart from that, personifi ed evaluation of delayed cardiovascular mortality for patients with precursory PCI must promote RF correction programme development, improvement of observation for high-risk patients, the patients' motivation enhancement and justifi cation of application of more intensive schemes of secondary prevention in the preoperative period and after performance of the intervention [19] . The FAME 2 study aimed at scientifi c justifi cation for recommendations regarding the PCI performance strategy based upon assessment of the fractional fl ow reserve (FFR) for all functionally signifi cant stenoses. Among 1220 patients with angiographically signifi cant stenoses, individuals with at least one functionally signifi cant stenosis (FFR ≤ 0.80) were identifi ed and consequently randomised into a PCI subgroup with FFR+OMT and a subgroup undergoing OMT only. Primary end points of the study were death, MI and the necessity of emergency revascularisation.
The amount of the randomised patients totalled 888 (447 in the PCI group and 441 in the OMT group). The frequency of end points in the PCI group was lower than in the OMT group (13.9% vs 27.0%; risk ratio, 0.46; 95% confi dence interval 0.34-0.63; р < 0.001) after 5 years of observation. In general, the study proved that PCI with stenosis functional signifi cance evaluation in the setting of stable IHD have advantage over OMT in terms of deaths, MI, emergency revascularisations in fi ve years of observation [20] . It follows from the aforesaid that the combination of PCI with OMT has the largest clinical and prognostic effects on treatment results. Optimal PCI result may be expected in cases when indications to treatment are objectivised (including application of ischaemia verifi cation methods) and the patient is assigned personalised medication.
Modifi able risks before elective PCI: prognostic signifi cance of medical therapy in the period of preoperative preparation
Patients with indications to myocardial revascularisation, notwithstanding the choice of its method, must receive medical therapy according to recommendations of the European Society of Cardiology due to its confi rmed promotion of symptom reduction and prognosis improvement [3] . Procedures aimed at lifestyle change and secondary prevention goals achievement (monitoring of arterial blood pressure (ABP), lipids, glycaemia, smoking cessation, weight normalisation) must begin before revascularisation and continue actively after the intervention [2] . All stable patients with an established IHD diagnosis are indicated for annual control of lipid, blood creatinine and glucose metabolism levels (class 1, level C). Use of aspirin, statins and angiotensin-converting enzyme inhibitors are recommended as medical therapy aimed at prevention of adverse events (class 1, level A). Lipid exchange impairment is an undisputed factor of cardiovascular risk as well as an irreplaceable predictor of both early and delayed complications. Monitoring of the level of low-density lipoproteins (LDL) plays an important role in decrease of these risks [21] . According to modern guidelines, IHD patients must intake statins (class of recommendations 1, level A) and achieve the target level of LDL [2] . Prescription of statins is a fairly simple, available and at the same time effective way to improve intervention results during the period of the patient's preparation for revascularisation. It has been shown that statins produce their protective effects not only by lowering the level of lipoproteins but also through their pleiotropic action that includes anti-infl ammatory, antiaggregatory impact, stabilisation of atherosclerotic plaques and endothelial function improvement [22] . Use of statins before CABG exerted preventive effect on postoperative cognitive dysfunction [23] , and safe cognitive status, in turn, facilitated higher adherence to treatment [24] . It has been shown that statin therapy prior to PCI also renders positive effect on the prognosis of patients with stable angina [25] . Protective humoral action of statins in the group of patients with DM type 2 was studied within the framework of the ANDROMEDA study [26] . The results the study that enrolled 509 patients receiving 10-20mg atorvastatin or 10-20mg rosuvastatin during 16 weeks demonstrated comparable decrease in the level of highly sensitive C-reactive protein despite a more pronounced hypolipidemic effect of rosuvastatin. The COMETS study demonstrated analogical results [27] . The CARDS study [28] , within the framework of which the effect of 10mg/day on the combined endpoint including death, nonfatal MI, hospitalisation with progressive angina, repeat revascularisation and brain stroke, showed that patients with DM type 2 had the frequency of adverse events in patients who received statin was 5.8% while that in the placebo group amounted to 9.0% (р=0.001) [29] . Effects of statin therapy in the preoperative period for PCI patient has been evaluated in a number of studies. In the ARMYDA study, patients (n=153) were randomised into the group with 40mg/day atorvastatin intake and the placebo group 7 days prior to elective PCI. The frequency of perioperative MI was 5% among patients receiving atorvastatin one week prior to PCI and 18% in the placebo group (р=0.025) [30] . The NAPLES (Novel Approaches for Preventing or Limiting Events) study, which enrolled 668 patients, had a slightly different design. That study prescribe a higher dosage of atorvastatin -80mg/day, randomisation was performed one day prior to PCI, the control group continued the earlierprescribed therapy and the frequency of perioperative MI totalled 9.5% and 15.8%, respectively (risk ratio 0.56; 95% confi dence interval: 0.35-0.89; p=0.014) [31, 32] . In 2018, a collective of Irish scientists undertook an effortto stuy effects of postoperative statin therapy with increase dosage (120mg) for achievement of maximum protective effect. The study enrolled 207 patients randomised iinto 2 subgroups: subgroup A (80mg/12hrs atorvastatin with additional 40mg atorvastatin 2 hours prior to the procedure) an subgroup B (40mg/day atorvastatin in the regular mode). Preparation effi cacy was evaluated by the frequency of perioperative MI through measurement of highly sensitive troponin T. As a result, the frequency of perioperative MI amounted to 5.2% in the group of patients receiving 120mg atorvastatin and 10.9% in the group of 40mg atorvastatin intake. However, due to a small sample, no statistical validity was acquired [33] . Simultaneously with the possibility of reliable decrease in perioperative MI, application of statins has nephroprotective effect. Usage of 40mg/12hrs rosuvastatin is associated with reliably less pronounce increase of serum creatinine and cystatin C within the fi rst day after the contrast X-ray intervention [34] [35] [36] . Understanding of cardiorenal interactions makes it possible to conclude that the function of kidneysor, to be precise, their dysfunction -could be considered as a free-standing factor of cardiovascular risk. PCI as a method guided by injection of X-ray contrast preparations is by itself an acute kidney injury (AKI) risk factor. Contrast injection increases production of endothelin and adenosine which leads to vasoconstriction as well as increase of calcium concentration in cells. Decrease in renal blood fl ow leads to kidney injury through oxidative stress activation, osmotic nephrosis development in tubules and ischemia in exterior parts of renal medulla. Despite the fact that, in present, the only pathogenetically justifi ed method of AKI prevention and treatment is adequate hydration, a number of authors has been developing ways to decrease AKI risk by means of medical preparations: prescription of 40mg/day rosuvastatin during 7 daysprior to and 3 days after elective PCI lead to revealing AKI in only 2 patients (5.88%) and in 12 patients (27%) in the control group, p=0.04. Within the period of 48 hours after elective PCI, the control group showed growth of creatinine, cystatin C and NGAL, decrease in calculated GFR which pointed to persistence of pathological processes in the renal parenchyma. Therewith, no statistically signifi cant differences in kidney damage markers and calculated GFR were registered in patients who had received high doses of rosuvastatin [37] . Evaluation of individual AKI risk is obligatory (evidentiality class I, evidentiality level C) and it is also recommended for patients medicated with metformin to undergo evaluation of renal function immediately after contrast X-ray intervention (evidentiality class I, evidentiality level C) [3, 19] . Intake of 75-150mg/day aspirin is recommended to all patients with established IHD as it has a proved effect in relation to the prognosis (evidentiality class I, evidentiality level A) [2] . For all stable IHD patients after PCI, dual antiplatelet therapy (DAPT) is recommended. Its duration depends on the risk of haemorrhagic complications. Haemorrhage risk evaluation for patients is possible by means of PRECISE-DAPT an DAPT scales (evidentiality class IIb, evidentiality level A). However, such an approach did not fi nd wide-spread use and, as a consequence, did not acquire a high level of evidentiality [38] . Stable IHD patients may be considered for preliminary clopidogrel prescription, if there is a high probability of consequent PCI (evidentiality class IIb, evidentiality level C) [38] . Clopidogrel prescription (loading dose 600mg, then 75mg/day) against the background of aspirin intake is recommended in case of stable IHD for patients planned for PCI (evidentiality class I, evidentiality level A). Prescription of ticagrelor or prasugrel against the background of aspirin intake may be prescribed instead of clopidogrel to stable IHD patients with planned PCI provided consideration for ischemic complications (a high SYNTAX score, preceding stent thrombosis, localisation and amount of implanted stents) and potential haemorrhages (evidentiality class IIb, evidentiality level C) [38] . DAPT is not indicated for medically treated patients with stable IHD (without preceding IHD) as well as in case of absent MI in anamnesis [38] . As yet, there is no alternative for clopidogrel in case of patients with stable IHD and undergoing elective PCI [39] . The group of patients hospitalised for future PCI is heterogeneous and includes both patients without preceding MI or revascularisation procedures and patients with poststroke cardiosclerosis. According to the latest guidelines by the European Society of Cardiology regarding treatment of patients after MI with ST segment elevation, prescription of beta-adrenergic blocking agents (BB) is recommended for all patients with reduced ejection fraction (EF) and hearth insuffi ciency symptoms (class of recommendations 1, level A). The recommendations also denote the necessity of BB prescription to less serious patients after primary PCI if there are no contraindications nor symptoms of acute ventricular failure [40, 41] . Angiotensin-converting enzyme inhibitor as well as sartans are recommended for all patients with IHD and such states as arterial hypertension, DM, CHF or chronic kidney disease (class of recommendations 1, level A) [2] .
Arterial hypertension: tight arterial blood pressure control for prognosis optimisation
Arterial hypertension is the most prevalent comorbidity among IHD patients [42] . At that, target ABP values are defi ned as 140/90mmHg and offi ce systolic ABP target parameters should be 130/90mmHg and lower in patients receiving antihypertension medical therapy in case of high tolerability [43] . Within the framework of the SPRINT study, two target ABP levels (<140 and <120mmHg) were compared in over 9000 patients with high cardiovascular risk. However, patients with DM and stroke in anamnesis were excluded from the study. The results showed that more intense ABP decrease (the achieved level of systolic ABP was 121mmHg vs 136mmHg) was associated with decrease in the frequency of main cardiovascular events by 25% and in the overall death rate by 27% [44] . Despite the fact that arterial hypertension tends to be present in 100% IHD patients, and anti-hypertension therapy possesses a wide spectrum of medical preparations and their combinations, it is to be stated that the quality of ABP control remains improper [45] . Target ABP values for patients before elective revascularisation are not designated in current recommendations. However, a number of works demonstrates that tight control over ABP, including pulse blood pressure, before elective PCI leads to improvement of long-term results of the intervention and the pulse blood pressure index itself may be considered as a predictor for prognostic evaluation [46] .
Active detection of carbohydrate metabolism disorder and their infl uence of the revascularisation prognosis. Features in revascularisation for patients with carbohydrate metabolism disorder
High prevalence of carbohydrate metabolism disorder (CMD) and the trend toward its increase in the IHD patient population defi nes growth of attention to this comorbidity. Active detection of CMD in IHD patients could be considered as one of the fi rst stages of effective control over cardiovascular risk before elective revascularisation. In numerous international studies investigating CMD in patients undergoing elective PCI, it has been shown that oral test of glucose tolerance and measurement of HbA1 facilitated additional detection of DM in 16.2% cases, impaired glucose tolerance (IGT) in 24.5% cases and impaired fasting glycaemia in 1% cases [47] . According to the prognosis of the International Diabetes Federation, 642mil people will have DM by 2040. Signifi cant growth of DM prevalence has been registered in the Russian Federation (RF), as well as in all states. According to data from the federal DM registry of the RF, a total of 4.35 million people (3.0% of the population) were subject to regular medical check-up by the end of 2016. Among them, 92% (4 million) had DM type 2, 6% (255 thousand) had DM type 1 and 2% (75 thousand) had other types of DM. However, these data underestimate the real amount of patients as only account for detected and registered cases of the disease. Thus, results of a large-scale Russian epidemiological study (NATION) confi rm that only 50% DM type 2 cases are registered [48] . Therefore, the real number of DM in the RF is not less than 8-9 million people (approximately 6% of the population) which is an extreme long-term threat as a signifi cant amount of patients remain undiagnosed and thus do not receive treatment and are at high risk of vascular complication development [49, 50] . Within the framework of the BARI 2D [51] , randomised comparison of OMT with revascularisation (both CABG and PCI) for DM patients was carried out. After selection of PCI or CABG as an optimal strategy, the patients were randomised into groups of OMT as a single treatment approach and OMT in combination with revascularisation. After fi ve years, no large differences were found in the combined endpoint: death, MI or stroke, which were 12% in both OMT and OMT in combination with revascularisation. The CABG group showed a signifi cantly lower frequency of major cardiac or cerebrovascular adverse events (78%) than that in the OMT group (70%, p=0.01). However, no difference in survivability was registered (CABG 86%, OMT 84%, р=0.33). Neither substantial difference in major adverse events nor survivability were revealed between the OMT group and the PCI group that included patients with predeterminedly lesssevere level of IHD than that in the CABG group. Throughout subsequent observation, 38% patients in the OMT group underwent at least one revascularisation due to development of the ischaemic clinical manifestations, while it was 20% for patients in groups of surgical initial treatment. Extrapolating these data on common practice, it is necessary to remember that the results were obtained in a selected population. Thus, the patients were excluded if they required immediate revascularisation or in presence of left main coronary artery stenosis as well as against the background of creatinine >177umol/l, HbA1c>13%, functional classes III-IV of CHF or PCI/CABG in medical history during the preceding 12 months. The risk of major cardiac events in patients with DM and dissatisfactory glycaemic control (HbA1c > 7%) was 2.1 times higher than for individuals without DM (adjusted risk ratio = 2.1, 95% confi dence interval: 1.10 to 3.95, p = 0.02). Despite this, in case of proper glycaemic control (HbA1c ≤ 7%), the risk of adverse events in DM patients does not have signifi cant differences from that for individuals without DM (adjusted risk ratio =1.33, 95% confi dence interval: 0.38 to 4.68, p = 0.66) [52] . Therefore, the evidence base in relation to infl uence of modifi ed RF on the prognosis regarding elective myocardial revascularisation is being formed at the present time. Additionally, confi rmedly effective means of their modifi cation have been determined.
Revealing and correction of modifi able risk factors in patients with stable IHD before elective PCI: the real state of the matter
It is known that the period of waiting for elective myocardial revascularisation often exceeds the recommended 6 weeks. Despite the importance of control over ABP, lipids and glycaemia levels, smoking cessation and body mass normalisation as confi rmed revascularisation result improvement tools, the actual quality of patient preparation is less than ideal in real clinical practice. The issue of suboptimal patient preparation before elective PCI is relevant to hospitals all over the world [45] . A large-scale project EUROASPIRE clearly demonstrates the insuffi ciency of attention to correction of modifi able RF in IHD patients even after preceding emergency or elective myocardial revascularisation (CABG/PCI). Analysis of over 16 thousand medical records in 24 European countries including the RF has shown that 93.8% patients received antiplatelet preparations; 82.6% patients received BB; 75.1% patients received angiotensin-converting enzyme inhibitors or sartans; 85.7% patients received statins. At that 16% of the respondents continue active smoking, 59.9% do not maintain a suffi cient level of physical exercise, 37.6% have the body mass index of over 30kg/m2, 42.7% do not reach the target ABP values (140/90mmHg), 80.5% have the level of LDL cholesterol over 1.8mmol/l, 26.8% have an established DM diagnosis . Therefore, the fact of adherence to treatment itself cannot be considered a synonym to OMT [45] . The basis of secondary prevention goals achievement is adherence to medical treatment and to recommendations regarding change of life style. However, among stable IHD patients undergoi9ng elective open revascularisation, only 19% patients received all 4 groups of recommended preparations before CABG (aspirin, statins, BB, angiotensin-converting enzyme inhibitors), 76% had elevated cholesterol levels , only 58% reached target levels of ABP [53] . In addition to initially higher risk of adverse events due to CMD, it has been demonstrated a number of major studies that patients with concomitant CMD fail to achieve correction of RF more often that patients without CMD [51] . Among patients enrolled in the BARI 2D study, high prevalence of smoking, uncontrolled hypertension, hypercholesteremia and combinations of the aforementioned factors [51] . Analogical analysis carried out in Japan has shown that only 18.2% patients had optimal control over the RF investigated in the study (ABP, lipids, glycaemia), at that 51.3% patients reached target ABP levels, 45.7% reached the target lipid profi le, 23% demonstrated glycated haemoglobin >7% from over 3 thousand patients. During division of the sample into subgroups depending on the presence of DM, it was determined that patients fail to reach target ABP, lipid and glycaemia values signifi cantly more often that individuals without diabetes. Therewith, protective effect of OMT in DM is signifi cantly more pronounced [54] . An analogical picture is seen in hospitals of the Russian Federation. Thus, 30% of 140 patients hospitalised in the SRI for Complex Issues of Cardiovascular Diseases for elective PCI in 2016 had different types of CMD, 88.5% (n = 124) had excess body mass with BMI over 25kg/m2, the average value of total cholesterol in the subgroup without CMD totalled 4.5mmol/l and 4.8mmol/l among patients with CMD [47] . These results demonstrate the necessity for more active work on RF correction for this category of patients. Another topical issue in actual clinical practice is insuffi cient and untimely diagnosis of DM on other forms of CMD.
During a retrospective analysis, we showed that CMD was revealed in 23.5% of patients with IHD and indications to elective PCI: 18.5% patients had DM, 5% had IGT, no impaired fasting glycaemia was revealed. Glycaemic status evaluation for IHD patients was carried out according to fasting glycaemia values and upon hospital admission. Active diagnostic search of CMD (glycated haemoglobin measurement, oral glucose tolerance test) was not performed for IHD patients. The majority of DM patients (91.8%) receive sugar-reducing therapy while 100% IGT patients do not undergo non-medication nor pharmacological therapy [55] . Procedures aimed at active diagnosis of CMD performed for the 140 patients admitted to elective PCI revealed 38.6% CMD that had not been diagnosed earlier [47] . Therewith, presence of diabetes defi nes the strategy of treatment for an important subgroup or patients with multi-vessel disease. In case of combination of multi-vessel disease and DM, the optimal revascularisation strategy is CABG that has signifi cant advantages over PCI in relation to mortality and new MI cases, especially in long-term observation. Consequently, DM not registered before choosing the revascularisation type leads to suboptimal decisions [56] .
Conclusion
Endovascular myocardial revascularisation is a highly technological less traumatic approach to improve the prognosis and the quality of life or IHD patients. Despite the contribution of such factors as smoking dyslipidemia, hypertension and hyperglycaemia into realisation of the unfavourable prognosis during stable IHD has been convincingly proved, the characteristics of patients admitted for elective PCI demonstrates insuffi cient carefulness risk correction at the stage of preparation for the surgery. An algorithm of individual patient preparation for PCI effective in the circumstances of actual clinical practice is to be developed. This will make it possible to avoid early and delayed complications and optimise treatment results.
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